Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028988 | 1.00 | STAT3 (0.54) | STAT3RAB9ABACE1LMNAMAPT | |
| SCHEMBL24358978 | 0.92 | STAT3 (0.52) | STAT3RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL6171194 | 0.86 | BACE1 (0.54) | STAT3RAB9ABACE1LMNAMAPT | |
| SCHEMBL3823935 | 0.86 | BACE1 (0.54) | STAT3RAB9ABACE1LMNAMAPT | |
| SCHEMBL28564359 | 0.84 | STAT3 (0.52) | STAT3RAB9ABACE1LMNAMAPT | |
| SCHEMBL4688054 | 0.83 | STAT3 (0.74) | STAT3RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL12226830 | 0.83 | STAT3 (0.74) | STAT3RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL4688056 | 0.83 | STAT3 (0.74) | STAT3RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL28571803 | 0.82 | BACE1 (0.50) | STAT3RAB9ABACE1LMNAMAPT | |
| SCHEMBL12190668 | 0.82 | TTR (0.56) | RAB9ABACE1ALDH1A1EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360079-A1 | PALLADIUM FREE PROCESSES FOR PREPARATION OF ACRYLATE COMPOUNDS | AMGEN INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4387951-A1 | PALLADIUM FREE PROCESSES FOR PREPARATION OF ACRYLATE COMPOUNDS | Amgen Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023023201-A1 | PALLADIUM FREE PROCESSES FOR PREPARATION OF ACRYLATE COMPOUNDS | AMGEN INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023201-A1 | PALLADIUM FREE PROCESSES FOR PREPARATION OF ACRYLATE COMPOUNDS | AMGEN INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| EP-2274280-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | Biolipox AB (SE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | STAT3 2164/4885RAB9A 3741/4885BACE1 1416/4885 |
| US-20240360079-A1 | PALLADIUM FREE PROCESSES FOR PREPARATION OF ACRYLATE COMPOUNDS | PTPRR, PTPRE, PTPRA | STAT3 4165/4885RAB9A 106/4885BACE1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.